Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
GMEDAUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over the prior year on an as-reported basis.
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
GMED(NYSE:GMED) AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc.
Globus Medical Reports Second Quarter 2025 Results
GMEDAUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
GMEDNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
A Look Into Globus Medical Inc's Price Over Earnings
GMEDJMP Securities Reiterates Market Perform on Globus Medicalto Market Perform
GMEDThis United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
GMEDAssessing Globus Medical: Insights From 4 Financial Analysts
GMEDBTIG Downgrades Globus Medical to Neutral
GMEDGlobus Medical Announces $500M Share Repurchase Program
GMEDTruist Securities Maintains Hold on Globus Medical, Lowers Price Target to $68
GMEDA Glimpse Into The Expert Outlook On Globus Medical Through 6 Analysts
GMEDPiper Sandler Maintains Overweight on Globus Medical, Lowers Price Target to $80
GMEDGlobus Medical Lowers FY2025 Adj EPS Guidance from $3.10-$3.40 to $3.00-$3.30 vs $3.40 Est; Raises FY2025 Sales Guidance from $2.66B-$2.69B to $2.80B-$2.90B vs $2.73B Est
GMEDGlobus Medical Q1 Adj. EPS $0.68 Misses $0.74 Estimate, Sales $598.12M Miss $625.90M Estimate
GMEDWhat Does the Market Think About Globus Medical?
GMED$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
GMEDHere's How Much You Would Have Made Owning Globus Medical Stock In The Last 10 Years
GMEDBreaking Down Globus Medical: 5 Analysts Share Their Views
GMEDTruist Securities Maintains Hold on Globus Medical, Lowers Price Target to $80
GMED$100 Invested In Globus Medical 10 Years Ago Would Be Worth This Much Today
GMEDHow Is The Market Feeling About Globus Medical?
GMEDTruist Securities Maintains Hold on Globus Medical, Lowers Price Target to $82
GMEDBreaking Down Globus Medical: 5 Analysts Share Their Views
GMEDNeedham Reiterates Hold on Globus Medicalto Hold
GMEDOsteoCentric Technologies Inks Non-Exclusive Licensing Agreement With Globus Medical
GMEDIf You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
GMEDLooking Into Globus Medical's Recent Short Interest
GMEDWhat Analysts Are Saying About Globus Medical Stock
GMEDHere's How Much You Would Have Made Owning Globus Medical Stock In The Last 10 Years
GMEDCitizens Capital Markets Reiterates Market Perform on Globus Medicalto Market Perform
GMEDBarclays Maintains Overweight on Globus Medical, Raises Price Target to $103
GMEDStifel Maintains Buy on Globus Medical, Raises Price Target to $94
GMEDWells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $93
GMEDNeedham Reiterates Hold on Globus Medicalto Hold
GMEDOn Stand-Alone Basis, Globus Medical Reaffirms 2025 Revenue Guidance Of $2.66B - $2.69B (Est $2.671B) And Adj EPS Of $3.40 - $3.50 (Est $3.43)
GMEDGlobus Medical Q4 2024 Adj EPS $0.84 Beats $0.75 Estimate, Sales $657.29M Beat $641.79M Estimate
GMEDCanaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $101
GMEDB of A Securities Upgrades Globus Medical to Neutral, Raises Price Target to $97
GMEDNeedham Reiterates Hold on Globus Medicalto Hold
GMEDStifel Maintains Buy on Globus Medical, Raises Price Target to $92
GMEDRoth MKM Reiterates Buy on Globus Medical, Maintains $100 Price Target
GMEDWhat 7 Analyst Ratings Have To Say About Globus Medical
GMEDRBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $92
GMEDWells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $88
GMEDPiper Sandler Maintains Overweight on Globus Medical, Raises Price Target to $100
GMEDB of A Securities Maintains Underperform on Globus Medical, Raises Price Target to $80
GMEDNeedham Reiterates Hold on Globus Medical
GMEDGlobus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.
GMEDGlobus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate
GMED